Jay Fine
President, Research & Development EvolveImmune Therapeutics, Inc.
Jay Fine is President, Research & Development at EvolveImmune Therapeutics. Jay possesses over 30 years of strategic leadership in drug discovery and development, covering immunology, immuno-oncology, inflammatory diseases, respiratory disorders and tissue fibrosis. Prior to joining EvolveImmune, Jay served as Senior Vice President, Global Therapeutic Area Head and Research Site Head at Boehringer Ingelheim in Ridgefield, CT and Biberach, Germany. His teams played seminal roles in the discovery and development of Skyrizi™, Spevigo™ and Jascayd™ and delivered over 30 molecules into clinical development. Previously, Jay held leadership positions at Roche and Schering-Plough, and at the National Cancer Institute. He received his B.S. degree from Cornell University and his Ph.D. degree from the University of Rochester Medical School. He is the author of over 75 scientific publications and patents and has received numerous honors and awards throughout his career.
Seminars
- EvolveImmune Therapeutics is pioneering next generation multispecific CD3-T-cell engagers (TcEs) with integrated CD2 costimulation, to optimize T-cell fitness for deeper and more durable patient benefits
- The EVOLVE platform provides superior T-cell activation, proliferation and tumor cell killing compared to first generation bispecific CD3-TcEs, without excess cytokine release or tonic T-cell activation
- EVOLVE104 is a trispecific TcE that binds to the UL Binding Proteins 2/5/6 (ULBP2/5/6) on tumor cells and both CD3 and CD2 on T-cells. EVOLVE104 demonstrates a promising preclinical profile, including enhanced T-cell activation and killing of ULBP2/5/6-positive tumor cells compared to first generation bispecific CD3-TcEs. No safety concerns were identified in nonclinical toxicity studies
- EVOLVE104 is currently being evaluated in a first-in-human Phase 1a/1b trial with advanced urothelial carcinomas and squamous cell carcinomas (NCT07217171). Study objectives include assessing the safety, efficacy, pharmacokinetics and pharmacodynamics of EVOLVE104 and identifying the recommended phase 2 dose (RP2D)
